Background/Objective: Many patients with psoriasis report that they are most bothered by
symptoms in difficult-to-treat, highly visible, pruritic areas, such as the scalp. Topical …

Background Many patients with psoriasis are bothered by symptoms in highly visible, pruritic
areas, such as the scalp. Objective To evaluate the efficacy and safety of apremilast for …

Efficacy and Safety of Apremilast in Patients With Moderate to Severe Plaque Psoriasis of
the Scalp: Results of a Phase 3, Multi Page 1 Presented at: Winter Clinical Dermatology …

Abstract Introduction and Objectives: Patients (pts) with moderate plaque psoriasis are often
inadequately treated (Armstrong, 2013), and there remains an unmet medical need for an …

Background: Apremilast 30 mg BID (APR) demonstrated efficacy in scalp and nail psoriasis
in patients with plaque psoriasis. Efficacy has not been investigated/reported in patients with …

INTRODUCTION: Many options are available for patients with moderate to severe plaque
psoriasis. Patients with moderate disease, however, are often undertreated and do not …

Background: Plaque psoriasis (PsO) with scalp involvement occurs in 65-80% of PsO (1, 2),
yet most patients are dissatisfied with scalp topical therapies (3, 4). Apremilast, an oral …

Background: Apremilast 30 mg BID (APR) provided greater improvements in scalp psoriasis
and quality of life vs placebo (PBO) in a phase 3 study in patients with moderate-to-severe …

DEAR EDITOR, Scalp psoriasis is common and often severe enough to negatively impact
quality of life (QoL). 1, 2 In STYLE (clinicaltrials. gov: NCT03123471), oral apremilast 30mg …

Introduction Psoriasis involvement in special areas (eg, scalp or nails) is associated with a
great disease burden yet it is often inadequately treated with topical treatments. The efficacy …